Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

被引：0
|
作者：
Li, He [1 ]
Liu, Jiazhuo [1 ]
Chen, Yuhui [1 ]
Tuohuti, Pazilaiti [1 ]
Wang, Yutong [1 ]
Tang, Xinzhu [1 ]
Xiang, Bing [1 ]
Jia, Yongqian [1 ]
Wu, Yu [1 ]
Tang, Yun [1 ]
Guo, Yong [1 ]
Wang, Jie [1 ]
Zheng, Yuhuan [1 ]
Liu, Yu [1 ]
Niu, Ting [1 ,2 ,3 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Facil Translat Med Sichuan, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy, Chengdu, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6308 / 6309
页数：2
相关论文
共 50 条
  • [21] A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naive marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety
    Xu, J-D.
    Cheng, L-Y.
    Li, J.
    Zhuang, J-L.
    Cheng, Z-X.
    Ren, Y-H.
    Zhang, Y-A.
    Wang, Y.
    Liu, P.
    ANNALS OF ONCOLOGY, 2024, 35 : S602 - S602
  • [22] Real-World Bruton Tyrosine Kinase Inhibitor Treatment Patterns, Compliance, Costs, and Hospitalizations in Patients with Mantle Cell Lymphoma in the United States
    Shah, Bijal D.
    Yang, Keri
    Liu, Sizhu
    Sivanantham, Jai
    Ali, Yasser
    Casten, Chris
    Satya, Swaroop
    Tang, Boxiong
    BLOOD, 2021, 138
  • [23] Extranodal marginal zone B-cell lymphoma arising in chronic myeloid leukaemia successfully treated with tyrosine kinase inhibitor: a case report
    Mihaylov, G.
    Varbanova, V.
    Stoeva, V
    Dikov, T.
    HIPPOKRATIA, 2016, 20 (03) : 241 - 243
  • [24] Efficacy Analysis of Bruton's Tyrosine Kinase Inhibitor Combined Regimen in the Treatment of Elderly Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma
    Shi, Wenyu
    Ben, Yu
    Zhang, Yaping
    Li, Jianyong
    BLOOD, 2022, 140 : 12121 - 12121
  • [25] ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IB/IIA DOSE-FINDING STUDY
    Li, R.
    Zhu, X.
    Liu, S.
    Zhang, X.
    Xie, C.
    Fu, Z.
    Huang, A.
    Sun, L.
    Liu, D.
    Zhao, J.
    Wu, L.
    Qin, Z.
    Li, S.
    Liu, Y.
    Li, Z.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 210 - 210
  • [26] Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naive human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting A retrospective cohort study
    Jacobson, Karen
    Ogbuagu, Onyema
    MEDICINE, 2018, 97 (43)
  • [27] Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
    Chang, Betty Y.
    Francesco, Michelle
    De Rooij, Martin F. M.
    Magadala, Padmaja
    Steggerda, Susanne M.
    Huang, Min Mei
    Kuil, Annemieke
    Herman, Sarah E. M.
    Chang, Stella
    Pals, Steven T.
    Wilson, Wyndham
    Wiestner, Adrian
    Spaargaren, Marcel
    Buggy, Joseph J.
    Elias, Laurence
    BLOOD, 2013, 122 (14) : 2412 - 2424
  • [28] Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer
    Meyerhardt, Jeffrey A.
    Heseltine, Denise
    Ogino, Shuji
    Clark, Jeffrey W.
    Enzinger, Peter C.
    Ryan, David P.
    Earle, Craig C.
    Zhu, Andrew X.
    Fuchs, Charles S.
    CLINICAL COLORECTAL CANCER, 2006, 6 (01) : 59 - 65
  • [29] RITUXIMAB WITH OR WITHOUT CHLORAMBUCIL FOR THE TREATMENT OF EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA: RESULTS OF A RETROSPECTIVE MONOCENTRIC STUDY
    Mannelli, L.
    Rigacci, L.
    Puccini, B.
    Kovalchuk, S.
    Benelli, G.
    Lancia, F.
    Bosi, A.
    HAEMATOLOGICA, 2015, 100 : 146 - 146
  • [30] Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting (vol 20, pg 1132, 2024)
    不详
    JCO ONCOLOGY PRACTICE, 2024, 20 (10) : 1436 - 1436
12345